GLOW vs KLOW vs Wolverine Stack: Which One?

The Three Names, Decoded

Search any of these names and you land on vendor pages, forum threads and dosing charts that assume you already know what is inside the vial. Most people do not. The names were coined by sellers and forums, not by chemists. KLOW is GLOW with a letter swapped to mark the added ingredient, and Wolverine borrows the comic-book character who heals from anything.

Here is the entire decoder. Wolverine is BPC-157 and TB-500, two peptides. GLOW is GHK-Cu Explore PeRxGHK-CuThe Skin Rejuvenation PeptideView peptide , BPC-157 and TB-500, three peptides. KLOW is GHK-Cu, BPC-157, TB-500 and KPV, four peptides. Each name is the previous one with something added.

PeRx dispenses two of the three. The Wolverine pair is the BPC/TB-500 combo Explore PeRxBPC/TB-500The Ultimate Recovery ComboView peptide . The four-peptide blend is KLOW, which the pharmacy supplies under that exact name. There is no GLOW product in the PeRx catalog, and this guide does not pretend otherwise. If a three-peptide skin-and-recovery blend is what you were looking for, the two prescribed routes are covered below.

Side-by-Side Comparison

Wolverine: The Recovery Pair

BPC-157 is a 15-amino-acid fragment of a protein found in human gastric juice. Its research base is almost entirely from one lab in Zagreb and almost entirely in rats, but it is deep, with tendon, ligament, muscle and gut-lining models going back to the early 1990s. In cultured tendon cells and in a rat Achilles model, BPC-157 increased tendon cell outgrowth, survival and migration, which is the mechanistic story most vendor pages are paraphrasing when they call it a healing peptide.

Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology. 2011;110(3):774-780. View study

TB-500 is the name gray-market sellers use for a synthetic fragment of thymosin beta-4, a 43-amino-acid protein present in nearly every human cell. Thymosin beta-4 binds actin, the scaffolding protein cells use to move, and in animal wound and cardiac models it promoted cell migration and tissue repair. The reason the two get paired is that they appear to work at different scales. BPC-157 concentrates its effect near the injection site; thymosin beta-4 fragments act systemically. Why we pair BPC-157 and TB-500 Read nextWhy We Pair BPC-157 With TB-500BPC-157 and TB-500 are both repair peptides, but they cover different ground. BPC-157 works fast and focal, strongest at a specific injury and in the gut. TB-500 works broad and systemic, moving repair cells across the whole body. The pairing is not automatic. Here is how a provider decides whether you need both, or whether BPC-157 on its own does the job.Read article goes through that reasoning in detail.

Goldstein AL, Hannappel E, Kleinman HK. "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends in Molecular Medicine. 2005;11(10):421-429. View study

PeRx does not sell TB-500 on its own. It ships only inside combinations, and the Wolverine pair is the BPC/TB-500 combo: 3 mg of BPC-157 and 3 mg of TB-500 per mL, together in one 5 mL vial. The recovery use case people actually bring to a clinic is almost always the pair, not TB-500 alone.

GLOW: Adding GHK-Cu

GHK-Cu is a copper-binding tripeptide first isolated from human plasma in 1973. It is the same molecule in copper peptide skincare, and most of its human data is topical: skin firmness, wrinkle depth and wound closure in cream or serum form. Gene-array work suggests it shifts expression of a large number of genes involved in collagen synthesis, tissue remodeling and inflammation, which is the basis for the claim that it does something broader than a moisturizer.

Pickart L, Margolina A. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." BioMed Research International. 2015;2015:648108. View study

GLOW exists because someone reasoned that if the Wolverine pair handles repair and GHK-Cu handles skin and connective tissue, a single vial could do both. The logic is fine. The evidence is not: there is no published human study of injected GHK-Cu combined with BPC-157 and TB-500, and the injected-GHK-Cu literature by itself is sparse. BPC-157 vs GHK-Cu Read nextBPC-157 vs GHK-Cu: Acute Repair vs Tissue RemodelingBPC-157 sends growth factor signals to fix an injury now. GHK-Cu rewrites gene expression to reverse tissue aging over time. One is a first responder. The other is a renovation contractor. They solve fundamentally different problems, which is why some patients use both.Read article lays out how differently the two peptides are thought to act, and the GHK-Cu guide Read nextGHK-Cu Copper Peptide: Skin, Hair & Tissue RepairIn 1973, a biochemist at UCSF discovered that young blood makes old cells act young. The molecule responsible was a tiny copper-binding tripeptide that drops 60% by age 60 and influences thousands of your genes. Today, TikTok sells it as a $20 face cream. The injectable version does something fundamentally different: it reaches every tissue in your body and tells them all to start repairing. Here's why that distinction matters more than any skincare trend.Read article covers the copper peptide on its own.

KLOW: Adding KPV

KPV is lysine-proline-valine, the last three amino acids of the hormone alpha-MSH. Researchers isolated it in 1989 because it kept the parent hormone's anti-inflammatory activity in lab models while dropping the pigment-darkening activity. The most-cited paper shows nanomolar KPV blocking NF-kB signaling in human intestinal cells and being carried into those cells by PepT1, a transporter that the colon switches on during inflammation. That is why the KPV conversation online is so gut-heavy. What is KPV Read nextWhat Is KPV? The Peptide Inside KLOWKPV is three amino acids long, which makes it one of the smallest molecules anyone calls a peptide. It came out of hormone research in the late 1980s, it has a real literature behind it, and almost none of that literature involves humans. Here is what is actually known, why PeRx only supplies it inside a four-peptide blend, and what the July 2026 FDA panel vote did and did not do.Read article covers the full research history.

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008;134(1):166-178. View study

KLOW is what PeRx dispenses under that name: BPC-157 at 3 mg per mL, GHK-Cu at 10 mg per mL, KPV at 3 mg per mL and TB-500 at 3 mg per mL, all in a 5 mL vial. It is the only way PeRx supplies KPV, and one of only three ways it supplies TB-500. The other TB-500 combos are BPC/TB-500 injectable and BPC/TB-500 capsules. The KLOW dosage guide Read nextKLOW Peptide Dosage: Chart, Frequency, CycleNearly every KLOW dosage chart online describes an 80 mg research vial that someone mixes at their kitchen table. The KLOW a physician actually prescribes is a different product with different math. This is the dosing as written on the PeRx prescription: units on the syringe, days per week, weeks per cycle, and what the gray-market charts get wrong.Read article walks through the prescribed schedule in more depth than this page does.

Which One Fits Your Goal

Strip away the nicknames and the decision comes down to what you are adding and whether you have a reason to add it. Each extra peptide is another substance with its own evidence gap and side-effect profile. GHK-Cu in particular carries real cautions: copper sensitivity, Wilson disease, and a pharmacy instruction to avoid copper supplements and vitamin C around the injection.

Prescribed Dosing at PeRx

Vendor dosage charts for GLOW and Wolverine are written for people mixing their own vials, which is why they read like arithmetic homework. A prescribed vial arrives at a fixed concentration, so the dose is a volume on an insulin syringe and nothing more. Every equivalent below is a 5 mL vial that ships fully reconstituted and ready to use, and every one is dosed at 20 units, which is 0.2 mL on a U-100 syringe. What changes between products is the milligrams that volume delivers.

Why $80 and $349 Are Not the Same Vial

The comparison people actually run in their head is GLOW at about $80 from a research site against KLOW at $349 from a clinic. Put that way, the clinic looks like a four-fold markup. It is not, because the two vials are different legal objects. The $80 vial is an unapproved substance sold without a prescription, labeled for research use and not for human consumption. That label is the legal basis on which the seller can ship it at all, and it means nobody has certified that the contents match the label, at the stated amount, sterile and free of endotoxin. A four-peptide blend multiplies that uncertainty by four.

The $349 vial is a compounded prescription. A licensed provider reviews your intake, and only if they approve is the order sent to a licensed 503A compounding pharmacy that prepares it for you specifically, under state board of pharmacy oversight, from pharmaceutical-grade starting material, as a sterile ready-to-use solution. The price covers the provider review, the compounding, sterility and potency requirements, cold-chain overnight shipping and the supplies. Research peptides vs prescription peptides Read nextResearch Peptides vs Prescription Peptides (2026)An honest comparison for the patient who already uses peptides, what the 'Not for Human Use' label actually means, the real quality differences, and the practical steps to switch from research-chemical sourcing to a prescription supply.Read article goes through the two categories line by line.

What the Evidence Does and Does Not Show

A stack guide that does not say this plainly is selling something. Of the four peptides across these three names, BPC-157 has the largest literature and it is almost entirely rodent work. TB-500 and thymosin beta-4 fragments have animal data and a small amount of early human work on the parent protein, none of it on the gray-market fragment as sold. KPV has no published human clinical study at all; the FDA review dated May 12, 2026 searched the major databases and found no data on KPV given to humans by any route. GHK-Cu has human data, but for creams, not injections.

There is also no published trial of any of the three combinations. Nobody has tested GLOW against Wolverine, or KLOW against either, in people. Every claim that one stack outperforms another is inference from single-ingredient animal studies, including the inferences on this page. What cannot be said is that any of them will produce a particular result in you.

The regulatory picture, as of August 27, 2026: on July 23 and 24, 2026 the FDA Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157, KPV and TB-500 for the 503A bulks list, in each case against the agency staff recommendation. Those votes are advisory. The FDA has not issued a rule since, and none of the four peptides is an FDA-approved drug. Injectable GHK-Cu was not part of that meeting and is slated for a second panel before the end of February 2027.

Common Questions